Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Paul Ausick | Oct 13, 2015 at 8:05 AM EDT

Johnson & Johnson Raises Forecast, Adds $10 Billion Buyback Plan

Johnson & Johnson reported mixed third-quarter 2015 results before markets opened Tuesday morning.

Jon C. Ogg | Oct 12, 2015 at 4:14 PM EDT

Aetna Seen Having Solid Upside in Independent Research Report

ThinkstockAetna Inc. (NYSE: AET) may be worth quite a bit more than its current price, and that might be the…

Chris Lange | Oct 12, 2015 at 1:55 PM EDT

What to Expect From Johnson & Johnson Earnings

Johnson & Johnson is scheduled to report its third-quarter financial results before the markets open on Tuesday.

Chris Lange | Oct 12, 2015 at 1:15 PM EDT

Can-Fite Biopharma Does It Again With Orphan Drug Designation

Can-Fite Biopharma announced that its oncology drug candidate has been granted Orphan Drug Designation by the European Medicines Agency (EMA).

Jon C. Ogg | Oct 12, 2015 at 10:55 AM EDT

Will Theravance Succeed in Staph and MRSA?

Theravance announced on Monday that Vibativ demonstrated positive clinical outcomes for patients with staphylococcus aureus (S. aureus) bacteremia and methicillin-resistant…

Jon C. Ogg | Oct 12, 2015 at 9:55 AM EDT

Eli Lilly Stumbles on Discontinued Drug Trial

Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.

Chris Lange | Oct 12, 2015 at 9:25 AM EDT

Short Sellers Become More Selective on Major Pharma

The September 30 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical…

Chris Lange | Oct 12, 2015 at 8:20 AM EDT

Short Sellers Increase Bets in Major Biotechs

The September 30 short interest data have been compared with the previous figures, and short interest increased in most of…

Chris Lange | Oct 9, 2015 at 11:20 AM EDT

Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher

Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's…

Lee Jackson | Oct 9, 2015 at 10:05 AM EDT

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Given the massive beat-down in the sector, if these companies surpass earnings expectations, the upside could be sizable.

Trey Thoelcke | Oct 9, 2015 at 7:05 AM EDT

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

Martin Shkreli has said he would lower the price of Daraprim back down but hasn’t actually done it. He probably…

Paul Ausick | Oct 8, 2015 at 1:35 PM EDT

What Johns Hopkins Study Reveals About Premature Births Near Fracking Wells

A new study published recently by the Johns Hopkins University Bloomberg School of Public Health has linked an increase in…

Chris Lange | Oct 8, 2015 at 11:45 AM EDT

Acelity Aims for Massive IPO

Acelity Holdings has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).

Lee Jackson | Oct 8, 2015 at 10:15 AM EDT

Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now

We scanned the Merrill Lynch stock coverage universe for specialty pharmaceutical stocks rated Buy and found three top companies that…

Chris Lange | Oct 8, 2015 at 9:10 AM EDT

Neurocrine Bio Soars on Positive Phase 3 Results

Neurocrine Biosciences made waves in the market on Thursday morning after it announced positive results in a Phase 3 trial.

1 … 240 241 242 243 244 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Johnson & Johnson Raises Forecast, Adds $10 Billion Buyback Plan

Aetna Seen Having Solid Upside in Independent Research Report

What to Expect From Johnson & Johnson Earnings

Can-Fite Biopharma Does It Again With Orphan Drug Designation

Will Theravance Succeed in Staph and MRSA?

Eli Lilly Stumbles on Discontinued Drug Trial

Short Sellers Become More Selective on Major Pharma

Short Sellers Increase Bets in Major Biotechs

Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

What Johns Hopkins Study Reveals About Premature Births Near Fracking Wells

Acelity Aims for Massive IPO

Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now

Neurocrine Bio Soars on Positive Phase 3 Results

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Health and Healthcare Articles

All Health and Healthcare Articles

Johnson & Johnson Raises Forecast, Adds $10 Billion Buyback Plan

Aetna Seen Having Solid Upside in Independent Research Report

What to Expect From Johnson & Johnson Earnings

Can-Fite Biopharma Does It Again With Orphan Drug Designation

Will Theravance Succeed in Staph and MRSA?

Eli Lilly Stumbles on Discontinued Drug Trial

Short Sellers Become More Selective on Major Pharma

Short Sellers Increase Bets in Major Biotechs

Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher

UBS Loves These 3 Top Biotech Stock Leaders Into Q3 Earnings

Generics Giants Like Teva and Mylan May Now Join the Buy-and-Raise Craze

What Johns Hopkins Study Reveals About Premature Births Near Fracking Wells

Acelity Aims for Massive IPO

Hot Political Rhetoric Hammers Specialty Pharmaceuticals: 3 to Buy Now

Neurocrine Bio Soars on Positive Phase 3 Results

The Reverse Mortgage Line of Credit That Grows Untouched for 15 Years and Becomes a $700,000 Liquidity Buffer at 80

Wealthy, Rich, or Upper Class? The retirement numbers at every tier

Bernstein Analyst: AI Agents Drive Chip Demand ‘Off the Charts,’ Supply Can’t Keep Up

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how